Elite Pharmaceuticals Inc (ELTP)

[BuddyGuise]

Global M&A Trends in Health Industries
From Pricewaterhouse Coopers 2024 Outlook

"Pharmaceuticals and life sciences (PLS) and healthcare services (HCS) M&A remained resilient in 2023, with innovative companies that can drive value attracting substantial investor interest. We expect dealmaking to accelerate off this baseline in 2024, as has already been observed with a pickup in M&A activity toward the end of 2023 and in the first few weeks of 2024."

"Biotech acquisitions to fend off patent cliffs: Large-cap pharma companies will continue to face patent cliffs and gaps in their pipelines in the latter half of this decade and will look for M&A opportunities to achieve their growth plans. Small and midsize biotech companies that can fill in pipeline gaps in the back half of the decade will receive significant attention in 2024."
https://www.pwc.com/gx/en/services/deals/trends/health-industries.html